PDUFA Date & Trial Timeline Calendar

Overview

This pillar tracks and analyzes critical FDA decision deadlines (PDUFA dates) and clinical trial milestones. It's essential for predicting the binary outcomes that drive the biotech and pharmaceutical sectors.

What It Does

It aggregates scheduled PDUFA dates and trial completion estimates from official sources like the FDA and clinical trial registries. The pillar then analyzes historical data for specific FDA review divisions and companies to calculate the probability of delays or extensions. This provides a forward-looking calendar of key events enriched with risk analysis.

Why It Matters

PDUFA dates and trial results are make-or-break events for biotech companies, often resulting in massive price swings. By quantifying the likelihood of schedule changes, this pillar offers an edge in timing predictions and identifying markets where the consensus timeline might be wrong.

How It Works

First, the system continuously scans FDA publications, company press releases, and trial databases for key dates. Each event is then categorized by drug, company, and review division. Finally, it compares the event to a historical database to generate a delay probability score, highlighting catalysts that are at high risk of being postponed.

Methodology

The core metric is the 'Schedule Risk Score', calculated by averaging the 5-year historical PDUFA extension rate for the assigned FDA review division with the specific company's track record for meeting its last three announced deadlines. Time windows for trial completions are estimated using enrollment rates and historical phase durations for similar drug classes.

Edge & Advantage

This pillar provides a data-driven probability of event delays, offering a significant edge over traders who only track the publicly announced dates.

Key Indicators

• PDUFA Date

  high

  The official deadline for the FDA to approve or reject a new drug application.

• Trial Data Readout

  high

  The estimated date for the release of clinical trial results (e.g., Phase 3).

• Historical Delay Rate

  medium

  The percentage of past deadlines that were extended for a specific FDA division.

• AdComm Meeting Scheduled

  medium

  Indicates if an FDA advisory committee will meet, often signaling a more complex or contentious review.

Data Sources

• FDA Calendar & Documents

  Official source for PDUFA dates and advisory committee schedules.

• ClinicalTrials.gov

  A comprehensive database of public and private clinical studies, including estimated timelines.

• BioPharmCatalyst

  A specialized third-party service that aggregates and tracks biotech catalyst events.

• Company Investor Relations

  Corporate press releases and SEC filings announcing trial timelines and regulatory updates.

Example Questions This Pillar Answers

• → Will [Company X]'s drug [Drug Y] receive FDA approval by its PDUFA date of [Date]?
• → Will [Company Z] announce positive Phase 3 trial results for its Alzheimer's drug before Q4 2024?
• → Will the FDA extend the review period for [Drug V] beyond its current PDUFA date?

Tags